SA
Go ProLog In
HRMY
OverviewIntelligenceChart
Next earnings: Aug 4, 2026 · Before open
Signal
Mixed1↑1↓
Price
1↓
Move↓-2.18%Negative session
Volume
1→
Volume↓0.5× avgLight volume
Technical
1↑
RSI↑RSI 53Momentum positive
PRICE
Prev Close
30.76
Open
30.90
Day Range29.91 – 30.90
29.91
30.90
52W Range25.52 – 40.87
25.52
40.87
30% of range
VOLUME & SIZE
Avg Volume
995.3K
FUNDAMENTALS
P/E Ratio
12.1x
Value territory
EPS (TTM)
—
Div Yield
No dividend
Beta
0.86
Market-like
Performance
1D
-2.18%
5D
-5.70%
1M↑
+2.98%
3M
-16.44%
6M
-11.58%
YTD↓
-19.59%
1Y
-12.09%
Best: 1M (+2.98%)Worst: YTD (-19.59%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +21% YoY · 77% gross margin
Valuation
CHEAP
P/E 12x vs ~20x sector
Health
STRONG
CR 3.6 · FCF $5.91/sh
Strong Buy
Key MetricsTTM
Market Cap$1.74B
Revenue TTM$899.11M
Net Income TTM$145.62M
Free Cash Flow$341.79M
Gross Margin76.5%
Net Margin16.2%
Operating Margin21.1%
Return on Equity17.2%
Return on Assets11.4%
Debt / Equity0.23
Current Ratio3.58
EPS TTM$2.52
Alpha SignalsView Intelligence →

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
5 strong1 watch
82/100
Liquidity
3.58Strong
Leverage
0.23Strong
Coverage
13.5xStrong
ROE
17.2%Strong
ROIC
12.5%Watch
Cash
$753MStrong
ANALYST COVERAGE13 analysts
BUY
▲ +52.9%upside to target
L $31.00
Med $46.00consensus
H $62.00
Buy
969%
Hold
215%
Sell
215%
9 Buy (69%)2 Hold (15%)2 Sell (16%)
Full report →
Stock Health
Composite Score
3 of 5 signals bullish
5/10
Technicals
●
RSI RangeRSI 53 — Bullish momentum
✓
Volume
●
Volume FlowDistribution — institutional selling
✗
Fundamentals
●
Last EarningsMissed estimates
✗
●
Analyst ConsensusBuy
✓
●
LiquidityCurrent Ratio 3.58 — healthy liquidity
✓
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentAug 31, 2026
In 107 days
Research
Fundamentals→Financials→Analysts→Earnings→Growth→Key Metrics→Technical Analysis→Intelligence→
Technicals
Technical SetupBULLISH
Technicals →

Trend

▲ RallyDeath Cross · 50D trails 200D by 11.0%

+3.1% vs SMA 50 · -8.3% vs SMA 200

Momentum

RSI53.1
Neutral territory
MACD+0.33
Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$40.87+35.8%
EMA 200
$32.25+7.2%
EMA 50
$30.54+1.5%
Current
$30.09
52W Low
$25.52-15.2%
52-Week RangeMid-range
$25.5230th %ile$40.87
Squeeze SetupVolume-based
Distribution Pressure

Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.

20-Day Money Flow
Acc days:4
Dist days:5
Edge:+1 dist
Volume Context
Avg Vol (50D)792K
Recent Vol (5D)
695K-12%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 8 analysts
Full estimates →
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$865.1M
$864.9M–$865.3M
—$3.20—
±9%
High6
FY2026(current)
$1.0B
$978.5M–$1.0B
▲ +16.8%$3.43▲ +7.1%
±23%
High8
FY2027
$1.1B
$953.1M–$1.3B
▲ +13.7%$4.13▲ +20.4%
±21%
High8
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryHRMY
Last 8Q
+49.7%avg beat
Beat 4 of 8 quartersMissed 4↑ Estimates rising
+433%
Q3'24
+18%
Q4'24
+15%
Q1'25
+32%
Q2'25
-13%
Q3'25
-5%
Q4'25
-55%
Q1'26
-28%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
Neutral — mixed activity
90d▲ 0▼ 1
Deutsche BankBuy → Hold
Feb 23
DOWNGRADE
UBSBuy → Neutral
Feb 11
DOWNGRADE
JefferiesBuy
Oct 14
UPGRADE
Zacks Investment Re…Hold
Apr 26
UPGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
Kapadia SandipCFO
$139K
Jan 26
SELL
Kapadia SandipCFO
$753K
Jan 15
SELL
Dayno Jeffrey M.Dir
$238K
Dec 12
SELL
Kapadia SandipCFO
$791K
Dec 5
SELL
Kapadia SandipCFO
$120K
Nov 21
SELL
Kapadia SandipCFO
$787K
Aug 15
SELL
Financials

INSTITUTIONAL OWNERSHIP

13-F Filings →
1
BlackRock, Inc.
7.1M▼
2
FMR LLC
3.2M▲
3
AMERICAN CENTURY COMPANIES INC
2.1M▲
4
DIMENSIONAL FUND ADVISORS LP
2.1M▲
5
LSV ASSET MANAGEMENT
2.0M▲
6
SG Americas Securities, LLC
2.0M▲
7
STATE STREET CORP
1.8M▲
8
ARMISTICE CAPITAL, LLC
1.6M▲
News & Activity

HRMY News

20 articles · 4h ago

About

Harmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. Harmony Biosciences Holdings serves patients in the United States.

Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Website
www.harmonybiosciences.com ↗
Jeffrey DaynoPresident, Chief Executive Officer & Director
Kumar BudurExecutive Vice President and Chief Medical & Scientific Officer
Adam ZaeskeExecutive Vice President & Chief Commercial Officer
Peers— Health Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt Cap↓P/ERev GrwMarginELO
HRMY◀
$30.09-2.18%$1.7B11.9+2150.7%1827.2%1500
BBIO
$66.13-5.07%$13.0B—+12626.1%-14525.8%1500
GH
$94.92-3.79%$12.6B—+3288.2%-4239.0%1500
MDGL
$523.69-3.00%$12.1B—+43205.3%-3008.0%1500
AXSM
$227.72-1.30%$11.7B—+6554.5%-2868.8%1500
BTSG
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
ARWR
$76.67-3.79%$10.8B—+2325815.3%-19.7%1500
Sector avg—-2.85%—31.1+342157.1%-3240.9%1500

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance